The 9 analysts offering 12-month price forecasts for Arrowhead Pharmaceuticals Inc have a median target of 89.00, with a high estimate of 106.00 and a low estimate of 45.00. The median estimate represents a +23.57% increase from the last price of 72.03.
The current consensus among 9 polled investment analysts is to Buy stock in Arrowhead Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.53
Reporting Date Feb 09
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.